In November 2014, a workshop in Basel brought together representatives from the EUCAST Steering Committee, the ESCMID Study Group for Mycobacterial Infections (ESGMYC), and the European Medicines Agency (EMA) to discuss data requirements for new anti-tuberculous drugs. A key outcome was the recognition of the utmost importance of identifying a reference method against which other methods can be calibrated — not least for the development of new agents, and to provide pharmaceutical companies with clear instructions on the data that must be submitted to EUCAST for the process of setting breakpoints for Mycobacterium tuberculosis complex and non-tuberculous mycobacteria.
The ESGMYC suggested setting up a subgroup to move forward with the next steps proposed in the workshop report. It was agreed that this would be organised as a EUCAST subcommittee.
Meetings for 2025-26 will be added soon.
Anyone with an interest in antimicrobial agents in general and antimicrobial breakpoints in particular is invited to contact EUCAST, ESCMID or one of the National Breakpoint Committees. To contact EUCAST use the contact form below.
We’ve prepared a short video to help you get familiar with the new layout and features.